In announcing the December 5, 2019 meeting of the Proposition 65 Cancer Identification Committee (CIC), OEHHA has published its Hazard Identification Document for acetominophen. Publication of the HID begins the public comment period on the document; the deadline for comments is November 4, 2019. Members of the public also may provide oral comments at the meeting.
Acetominophen is a widely used analgesic and antipyretic drug which first became available without a prescription in 1955. The HID, over 350 pages long, evaluates and summarizes a number of studies relating to this OTC drug. At the upcoming CIC meeting, committee members will discuss, and ultimately vote on, whether acetominophen should be added to the Proposition 65 list as a carcinogen.
If acetominophen is added to the list, the Proposition 65 warning requirement will become effective one year later. Manufacturers and sellers of this OTC drug then will surely need some of that pain relief.
Grimaldi Law Offices has been advising clients for over 20 years on chemical and product regulation. For knowledgeable advice and in-depth analysis on your chemical regulatory compliance obligations, contact Grimaldi Law Offices at (415) 463-5186 or email us at email@example.com.
This is attorney advertising.